Core Viewpoint - The study identifies a critical imbalance of NTRK2 isoforms in endothelial cells as a key driver of endothelial dysfunction in Bronchopulmonary Dysplasia (BPD), suggesting that mRNA therapy targeting NTRK2-FL could promote vascular regeneration and repair in affected lungs [3][5][7]. Group 1: Research Findings - The research reveals that the functional imbalance of NTRK2 isoforms in endothelial cells determines the regeneration outcomes of pulmonary microvessels after injury [3]. - A multi-omics analysis of endothelial cells isolated from human BPD lung tissue identified a common capillary endothelial cell (gCap) that is regulated by two different isoforms of NTRK2, with NTRK2-FL promoting repair and NTRK2-T1 leading to maladaptive responses [4][9]. - The use of lipid nanoparticle (LNP) delivered NTRK2-FL mRNA significantly restored capillary density and improved alveolar structure in a mouse model of hyperoxia-induced lung injury [4][9]. Group 2: Implications of the Study - The findings indicate that the isoform imbalance of NTRK2 is a critical factor in endothelial dysfunction, supporting the potential of isoform-specific RNA therapy as a promising strategy for vascular regeneration and repair [5][7]. - The research successfully demonstrates a method to revert the "bad switch" from NTRK2-FL to NTRK2-T1 back to a "good" state by restoring NTRK2-FL expression, thereby repairing damaged lung vasculature and alveolar structures [7].